Success Metrics

Active Trials

2(50%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Terminated(1)

Other(1)

Detailed Status

Recruiting2

Withdrawn1

Suspended1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

recruiting250%

withdrawn125%

suspended125%

Recent Activity

2 active trials

Showing 4 of 4

recruitingphase_1

RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV

NCT06484335

recruitingphase_1

The Tatelo Plus Study

NCT06508749

suspendedphase_1

Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy Participants

NCT05959707

withdrawnphase_1

Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission

NCT05769569

Clinical Trials (4)

Showing 4 of 4 trials

NCT06484335Phase 1

RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV

Recruiting

NCT06508749Phase 1

The Tatelo Plus Study

Recruiting

NCT05959707Phase 1

Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy Participants

Suspended

NCT05769569Phase 1

Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4